Please add the following claims.

9. (New) The method of claim 4, wherein the sample is a fluid sample.

B1

10. (New) The method of claim 9, wherein the fluid sample is blood.

11. (New) The method of claim 9, wherein the fluid sample is urine.

12. (New) The method of claim 4, wherein the subject is diabetic.

13. (New) The method of claim 4, wherein the subject is free of symptoms calling for a therapy with a sugar-regulating therapy.

14. (New) The method of claim 4, wherein the subject is undergoing therapy for regulating blood sugar levels.

15. (New) The method of claim 14, wherein the therapy is a non-drug therapy.

16. (New) The method of claim 14, wherein the therapy is a drug therapy.

17. (New) The method of claim 16, wherein the drug therapy is an oral blood sugar regulating agent therapy.

18. (New) The method of claim 16, wherein the drug therapy is an injectable drug therapy.

19. (New) The method of claim 16, wherein the drug therapy is insulin therapy or an insulin analog therapy.

20. (New) The method of claim 4, wherein the subject is at increased risk of becoming diabetic.

21. (New) The method of claim 4, wherein the control level is the level in apparently healthy normal individuals.

22. (New) The method of claim 4, wherein the control level is a predetermined value.

23. (New) The method of claim 4, wherein the control level is a level determined for the subject from a sample obtained from the subject at a time separated from the first sample.

24. (New) The method of claim 23, wherein the time is at least one day.

25. (New) The method of claim 4, wherein the subject has received treatment for regulating blood sugar levels.

26. (New) The method of claim 4, wherein the subject has not received treatment for regulating blood sugar levels.

B1

27. (New) The method of claim 4, wherein the condition is an abnormal blood sugar level.

28. (New) The method of claim 4, wherein the level is obtained using an immunoassay.

29. (New) The method of claim 4, wherein the level is measured as a percentage of the total CD59 in the sample.

30. (New) The method of claim 4, wherein the level is the level of K41-glycated CD59 relative to the level of K41-nonglycated CD59 in the sample.

31. (New) The method of claim 4, wherein the level is obtained using an agent that binds specifically to K41-glycated CD59.

32. (New) The method of claim 31, wherein the agent is detectably labeled.

33. (New) The method of claim 31, wherein the agent is an antibody or antigen-binding fragment thereof.

34. (New) The method of claim 33, wherein the antibody is a monoclonal antibody.

35. (New) The method of claim 33, wherein the antibody is a polyclonal antibody.

36. (New) The method of claim 4, wherein the level is obtained using two agents, a first agent that binds both glycated and nonglycated CD59 and a second agent that binds only one of a glycated K41 and a nonglycated K41.

37. (New) The method of claim 36, wherein one or more of the first and second agents is detectably labeled.

38. (New) The method of claim 36, wherein one or more of the first and second agents is an antibody or antigen-binding fragment thereof.

39. (New) The method of claim 38, wherein one or more of the first and second antibodies is a monoclonal antibody.

40. (New) The method of claim 38, wherein one or more of the first and second antibodies is a polyclonal antibody.